BioXcel Therapeutics, Inc.

Analysis for Ticker: BTAI

BioXcel Therapeutics Inc uses an artificial intelligence platform called EvolverAI to find new uses for old drugs in the fields of neuroscience and cancer. But the reality is a financial machine that spent 69,9$ million in 2025 just to generate 642.000$ in sales. It is like one bakery that spends seventy dollars on electricity and flour just to sell one cookie for sixty cents. The math is a disaster because the company survives by printing free pieces of itself for its leaders while borrowing millions of dollars at high interest rates that it cannot pay back. The mechanism of wealth transfer began in 03/2022, when the company started giving free shares, called restricted stock units, to insiders. Chief executive Vimal Mehta received 2.609 units, while lieutenants Richard Steinhart, Javier Rodriguez, and Frank Yocca each received 521 units. By 04/2022, the company signed a massive debt agreement with lenders led by Oaktree Fund Administration. The business lost 165,8$ million that year. In 03/2023, the leaders gave themselves more free paper, handing Mehta 3.500 units and 562 units to each of the others. The losses grew to 179,1$ million in 2023, yet Mehta took home 4,7$ million in total pay.